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InTRoduCTIon
Candida glabrata is the second most common cause of 
candidemia in the USA [1] and its prevalence is increasing 
worldwide [2, 3]. Acquisition of resistance to azoles, 
echinocandins, amphotericin B and multidrug resistant 
(MDR) traits are alarming features of C. glabrata [3–5]. 
For a decade C. glabrata has been recognized as a cryptic 
species complex containing the emerging opportunistic 
yeast species C. nivariensis [6] and Candida bracarensis 
[7]. These species belong to the Nakeseomyces clade of 
the Saccharomycotina [8]. Comparative genomic studies 
showed that C. bracarensis and C. nivariensis are more 
related to the non-pathogenic yeast species Nakaseomyces 
delphensis than to C. glabrata [8].
Although some studies showed that time-consuming, 
but relative simple phenotypic identification techniques, 
such as CHROMagar, can easily distinguish these species 
from C. glabrata, molecular assays increased the accuracy 
and shortened the identification turn-around time [9]. 
Moreover, not only is little known about their virulence, 
antifungal susceptibility and prevalence, but also rarity of 
spectra of these species has hampered the accuracy of Vitek 
MS to correctly identify clinical isolates of C. bracarensis 
and C. nivariensis [10]. Accordingly, identification and 
sharing data on nationwide and worldwide scales could 
enrich our knowledge about various aspects of these species 
and will contribute to diagnostic and even therapeutic 
improvement.
Here, we retrospectively studied a large collection of clinical 
C. glabrata isolates recovered from Iranian patients. Subse-
quently, amplified fragment length polymorphism (AFLP) 
fingerprinting [11], antifungal susceptibility patterning, using 
Abstract
Purpose. Identification of the emerging yeast species Candida nivariensis among presumptively identified Iranian Candida 
glabrata isolates.
Methodology. Clinical C. glabrata species complex isolates from blood (n=100; 46.9%), vaginal swabs (n=20; 9.4%), bronchoal-
veolar lavage (n=10; 4.7%) and sputum (n=12; 5.6%) from 68 patients from Iran were investigated. Isolates were characterized 
by CHROMagar, multiplex PCRs, matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS), 
amplified fragment length polymorphism (AFLP) fingerprinting, internal transcribed spacer (ITS)/large subunit (LSU) rDNA and 
FKS1/FKS2 sequencing, and the European Committee on Antimicrobial Susceptibility Testing broth microdilution method. A 
comprehensive literature review was conducted and all the relevant clinical and microbiological data were collected.
Results. Four C. nivariensis isolates were recovered from blood samples of three subjects and were all consistently identified 
by nine-plex PCR, Bruker MALDI-TOF MS, and LSU and ITS rDNA sequencing. AFLP genotyping clustered the isolates into two 
groups. Sequencing of the FKS1 and FKS2 hotspots showed no accountable amino acid substitutions. All isolates were suscep-
tible to amphotericin B, fluconazole, itraconazole, posaconazole, voriconazole, anidulafungin and micafungin.
Conclusion. In total, 4 out of 213 clinical C. glabrata species complex candidemia isolates were C. nivariensis. Improvement of the 
BioMerieux Vitek MS database is required to accurately identify C. nivariensis and it is advised to alternatively use CHROMagar 
and/or PCR-based techniques. As other species within the Nakaseomyces clade may cause infection and showed high MIC 
values for antifungals, inclusion of their spectra into the MALDI-TOF MS database seems relevant. Due to developing resistance 
to fluconazole and insufficient efficacy of caspofungin, the combination of catheter removal plus treatment with caspofungin, 
or voriconazole, or micafungin might be effective for patients.
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European Committee on Antimicrobial Susceptibility Testing 
(EUCAST) broth microdilution, and sequencing of the FKS1 
and FKS2 hotspot 1 (HS1) regions were performed. Lastly, 
a comprehensive literature review was performed to collect 
relevant clinical and microbiological data of C. nivariensis 
cases.
METHodS
Retrieving data of published cases
All published studies containing C. nivariensis cases from 
2005 (year of description of the species C. nivariensis) to 
1 October 2018 were retrieved. The keyword ‘Candida 
nivariensis’ without any limitations in languages and dates 
was searched in PubMed and Google search engines.
Clinical aspects, including year of publication and location, 
age, sex, sample type, risk factors and underlying conditions, 
antifungals used and duration of therapy, outcome and 
microbiological data, including number of isolates, pheno-
type on CHROMagar, antifungal susceptibility testing (AFST) 
protocol, and the MIC values for the antifungals fluconazole 
(FLC), voriconazole (VRC), itraconazole (ITC), posaconazole 
(PSC), caspofungin (CSP), micafungin (MCF), anidulafungin 
(ANF), amphotericin B (AMB), and 5-fluorocytosine (5FC) 
were recorded. In order to assure the accuracy of collected 
clinical and microbiological data, they were checked and 
recorded by two individuals to reach consensus.
Patient information
Case 1 (isolate 2n)
A 67-year-old man, who underwent mitral and aortic valves' 
repair, two months after cardiac surgery and with clinical 
neurological deficits compatible with cerebrovascular acci-
dent (CVA) was admitted in Ghaem hospital, Mashad, Iran, 
on 5 April 2015. Brain MRI (T1 with contrast view) revealed 
two ring enhancement masses on right frontal and temporal 
lobes that suggested brain abscesses. After this primary diag-
nosis, some masses were visible around the mitral valve on 
his Trans esophageal echocardiography (TEE). With being 
suspicious of mitral valve endocarditis, a blood sample was 
taken and incubated in Bactec device (Bactec 9420, Becton 
Dickinson, Franklin Lakes, NJ, USA). Broad spectrum anti-
biotics, including cefepime 2 g/IV/TDS, gentamicin 80 mg/
IV/TDS, rifampin 300 mg/PO/BD and vancomycin 1 g/IV/
BD were prescribed after blood culture sampling. After 36 h, 
the blood culture was positive for Enterobacter spp. Vanco-
mycin was discontinued and other antibiotics continued 
and his fever completely resolved after 7 days. On 18 April 
fever started again, hence, the blood sample was taken and 
after 48 h it was positive for Candida spp. Caspofungin 
(70 mg/IV/stat and 50 mg/IV/daily) was added to the previous 
antibiotic regimen and this treatment was continued for 
10 days. His follow-up blood culture was negative after 3 days. 
Despite being partially recovered, due to his family member's 
request, he was discharged while he was under treatment with 
fluconazole (400 mg daily/PO) 22 days post admission.
Case 2 (isolate 5n)
The same patient (case 1) after 30 days with fever complaint 
was referred to Ghaem hospital and admitted to the infection 
ward on 26 May 2015. He described his previous frequency 
of dysuria 5 days before admission and he was evaluated for 
urosepsis. Urine analysis revealed the presence of many white 
blood cells (leukocyturia) and yeast cells (>105 c.f.u. ml−1) 
and accordingly AMB deoxycholate (75 mg/IV/ daily) was 
prescribed. A blood sample was taken and after 6 days incu-
bation yielded yeast cells. Although, not fully recovered and 
his general health status was not satisfactory for the medical 
team, the patient left the hospital and no information was 
available on his follow-up.
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Case 3 (isolate 35n)
A 14-year-old girl with severe burnings was hospitalized 
in the burn intensive care unit (ICU), Ghaem Hospital, 
Mashhad, Iran, on 26 October 2015. The whole upper body 
part, neck and face were involved with second to third 
degree burns. In the beginning of her admission, she was 
alert and in order to relieve the pain, fentanyl (50 µg/IV/
infusion/hour) was prescribed for a few days and daily 
washing and dressing of wounds were performed. The 
first episode of fever was noticed 7 days post admission. 
Physical examinations showed that there was a significant 
infection of the burn wounds. Hence, wound drainage 
and blood were subjected to culture, and imipenem (500 
mg/IV/QID) and vancomycin (1 g/IV/BID) treatments 
were started. The blood and wound drainage culture 
yielded both Acinetobacter baumannii, vancomycin 
was replaced by colistin (9 mu/IV/loading and then 
4.5 mu/IV/BID) and she was treated with both colistin and 
imipenem. After 2 days, fever signs were eliminated and 
first debridement surgery was performed. On the fourteenth 
admission day, the affected site was repaired with allograft 
skin surgery. Then 3 days after the surgery (seventeenth day 
of admission), the patient became febrile and discharges 
were observed around the skin graft. A blood sample yielded 
an imipenem and amikacin resistant strain of Pseudomonas 
aeruginosa and Candida spp., while the wound culture 
remained negative. Imipenem treatment was stopped and 
meropenem (2 g/TDS/IV) and fluconazole (200 mg/daily/
PO) were added to colistin. On the twenty-first day of admis-
sion, blood cultures remained positive with Pseudomonas 
aeruginosa and Candida spp. On 26 November 2015, in spite 
of the extensive debridement of the graft and the replace-
ment of fluconazole with amphotericin B deoxycholate 
(50 mg/daily/IV) the patient succumbed.
Case 4 (isolate 81)
A 62-year-old female with left limb sarcoma was admitted with 
necrotizing fasciitis and severe sepsis in the emergency ward in 
Imam Khomeini complex hospital, Tehran, Iran, on 23 July 2018. 
Treatment with meropenem (1 gr/TDS/IV) and vancomycin 
(1 g/IV/BID) was started and amputation of the left limb was 
immediately performed. During 24–26 July, despite antibiotic 
therapy and amputation, the patient was suffering from fever and 
sepsis. Hence, being suspicious for an infection caused by other 
micro-organisms, blood samples were taken and incubated in 
Bactec 9420 device (Becton Dickinson). On 26 July, following 
the isolation of Pseudomonas aeruginosa from a wound culture 
of the amputated leg discharges, colistin (9 mu/IV/Loading and 
then 4.5 mu/IV/BID) and gentamycin (240 mg/IV/TDS) were 
administered and treatment with vancomycin was stopped. 
On 27 July, blood cultures yielded yeast cells and subsequent 
PCR reported them as C. glabrata and antifungal therapy with 
300 mg of liposomal amphotericin B was started the following 
day. On 29 July, liposomal AMB was replaced with 50 mg of 
caspofungin. On 8 August 2018, the patient died due to septic 
shock and cardiac arrest.
Isolates, identification, and part sequencing of FKS1 
and FKS2 genes
Preserved clinical isolates of C. glabrata (2015–2018) from 
four metropolitan cities of Iran, including, Tehran, Shiraz, 
Isfahan and Mashhad, were retrospectively collected. Isolates 
were obtained from blood (n=71; 33.3%), urine (n=100; 
46.9%), vaginal swabs (n=20; 9.4%), bronchoalveolar lavage 
(BAL) fluid (n=10; 4.7%) and sputum (n=12; 5.6%) samples. 
Isolates were streaked on Saboraud dextrose agar at 37 °C 
for 24–48 h. Colonies that showed white and pink colonies 
on CHROMagar were selected and subjected to a compre-
hensive multiplex 21-plex PCR [12]. Further analysis by a 
nine-plex PCR [9], Bruker MALDI-TOF MS (Microflex LT, 
Bruker Daltonics, Bremen, Germany), large subunit (LSU) 
and internal transcribed spacer (ITS) rDNA sequencing, 
antifungal susceptibility testing (EUCAST v9.0) and AFLP 
was performed. Identification by MALDI-TOF MS was 
performed using a full extraction method [13]. In order to 
evaluate the accuracy of MALDI-TOF MS and the nine-plex 
PCR, sequencing of LSU of ribosomal DNA (rDNA) using 
primers of LROR (5′-ACCCGCTGAACTTAAGC-3′) and 
LR5 (5′-TCCTGAGGGAAACTTCG-3′), and ITS rDNA 
using primers of ITS1 (5′-TCC GTA GGT GAA CCT GCG 
G-3′) and ITS4 (5′-TCC GTA GGT GAA CCT GCG G-3′) 
was performed [14].
C. glabrata increasingly shows resistance to echinocandins 
that is mainly associated with acquisition of mutations in the 
hotspot 1 (HS1) of FKS1 and FKS2 genes [15]. C. nivariensis 
is phylogenetically closely related to C. glabrata, therefore, 
we sequenced HS1 of these two genes for the isolates of 
C. bracarensis and C. nivariensis. Primers targeting HS1 of 
FKS1 (389 bp) and FKS2 (718 bp) of C. glabrata were used 
for this purpose (unpublished data).
Genotyping of isolates of C. nivariensis using AFLP
In order to investigate the genetic relationship and genotypic 
diversity of our isolates, AFLP was followed as described 
before [11]. Besides our clinical isolates of C. nivariensis 
(n=4), CBS reference and type strains of C. nivariensis (CBS 
9984, CBS 9985 and CBS 10161), C. bracarensis (CBS 10154) 
and a clinical isolate of C. bracarensis (H111) generously 
provided by Professor W. Liao (Shanghai, China), C. glabrata 
(CBS 138), C. uthaithanina (CBS 10932), C. kungkrabaensis 
(CBS 10927), N. delphensis (CBS 2170) and N. bacillisporus 
(CBS 7720) were included in the AFLP experiment.
Antifungal susceptibility testing
To define the MIC of our isolates, antifungal susceptibility 
testing was performed using broth microdilution procedure 
of EUCAST version 9.0 ( www. eucast. org/ fileadmin/ src/ 
media/ PDFs/ EUCAST_ files/ AFST/ Clinical_ breakpoints/ 
Antifungal_ breakpoints_ v_ 9. 0_ 180212. pdf). Amphotericin B 
(AMB), 5-flucytosine (5FC; Sigma Chemical Corporation, St. 
Louis, MO, USA), fluconazole (FLC), voriconazole (VCZ) and 
anidulafungin (AND; Pfizer, New York, NY, USA), itracona-
zole (ITC; Santa Cruz Biotech, Dallas, TX, USA), posaconazole 
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(PSC; MSD, Kenilworth, NJ, USA), and micafungin (MCF; 
Astellas Pharma, Tokio, Japan) were included. As caspofungin 
is associated with interlaboratory variations and obtained 
MIC values of this drug cannot differentiate wild-type and 
mutated strains of C. glabrata [16], we did not include this 
drug in our antifungal susceptibility assessment. It is known 
that MIC values obtained for anidulafungin and micafungin 
better predict the presence of mutations in FKS1 and FKS2, 
and thus both echinocandins were included [16]. AMB, AND, 
FLC and MCF were interpreted based on clinical breakpoints, 
while ITC, PSC, VRC and 5FC were interpreted based on 
epidemiological cut-off values. For antifungal susceptibility 
testing, apart from our clinical isolates of C. nivariensis (n=4), 
four reference and type strains of C. nivariensis (CBS 9983, 
CBS 9984, CBS 9985 and CBS 10161) were included.
RESuLTS
data obtained from published cases of C. 
nivariensis
All clinically and microbiologically relevant data of published 
literature and our cases are presented in Tables S1 and S2 
(available in the online version of this article). In total, 75 
C. nivariensis isolates were found in 13 countries. Isolates of C. 
nivariensis were recovered from four continents and Europe 
with 39 isolates had the highest number of isolates, followed 
by Asia with 30 isolates, America with 4 isolates and Australia 
with only 1 isolate. Country-wise, China contained the highest 
number of isolates of C. nivariensis (n=20), followed by the 
UK (n=16), Poland (n=14), Spain (n=8), India (n=6), Argen-
tina (n=3), Malaysia (n=2), and Australia, Brazil, France, 
Indonesia, Italy and Japan reported only one isolate. The 
majority of infections caused by C. nivariensis were found in 
adults aged >20 years (89.65%) with a median age of 62 years. 
Two-thirds of cases of infections (n=29) (with known data of 
age and sex) were acquired by women and the rest by men 
(n=10). C. nivariensis isolates were recovered from a wide 
ranges of clinical samples, including blood (n=18), vagina 
(n=17), urine (n=6), BAL and tracheal aspirate (n=4), peri-
toneal fluid (n=6), oral samples (n=3), abscess (n=2), urine 
and renal catheter (n=2), vascular tip catheter (n=2), sputum 
(n=2), CSF (n=2), pleural fluid, urorstomy fluid, lung biopsy, 
pelvic collection, nasal secretion, exit site swab, nail with each 
one sample (for three samples no source was mentioned). 
Candidemia (24%), vaginitis (22.66%) and candiduria (8%) 
were among the most prevalent clinical manifestations caused 
by C. nivariensis. Broad-spectrum antibiotic therapy and 
catheter insertion were the most encountered risk factors 
for development of candidiasis due to C. nivariensis. Among 
18 patients with candidemia due to C. nivariensis, treatment 
option and clinical outcome (death/survival) were reported 
for only three and four patients, respectively. These three 
patients were primarily treated with fluconazole and during 
the course of infection, fluconazole was changed to voricona-
zole and micafungin followed by micafungin alone (n=1), or 
catheter removal and CSP (n=1), or CSP treatment (n=1). 
From these three patients two were treated with VCZ plus 
MCF or CSP plus catheter removal survived, while the one 
treated with CSP died. With respect to cases with vaginitis, 
FLC was the most frequently used antifungal (n=10/16), 
followed by miconazole (n=3/16), boric acid in combination 
with ITC and chlorhexidine (n=2/16), and FLC in combina-
tion with nystatin (n=1/16). From these 16 vaginitis cases only 
12 mentioned clinical oucome, among them four out of eight 
individuals administered with FLC, two out of three patients 
treated with miconazole, and one individual treated with the 
combination of FLC and nystatin showed recurrent vaginitis.
Comparison of identification systems and 
sequencing of HS1 FKS1 and FKS2
Using 21-plex PCR, 213 clinical isolates were identified as 
C. glabrata. In contrast, the nine-plex PCR identified four 
isolates of C. nivariensis and no C. bracarensis in agreement 
Fig. 1. Successful identification of C. nivariensis isolates using nine-plex PCR.
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with MALDI-TOF MS (green scores>2) and sequencing 
of LSU rDNA (Fig. 1). In total, 4 out of the 213 Iranian 
C. glabrata species complex isolates were C. nivariensis 
and the rest were C. glabrata. Interestingly, all isolates of 
C. nivariensis were from blood samples and were obtained 
from Mashhad in 2015 (n=3) and Tehran in 2018 (n=1) that 
comprised 4.41% of the Iranian candidemia cases caused by 
C. glabrata.
Despite the fact that primers targeting HS1 of FKS1 and FKS2 
were based on the corresponding sequences of C. glabrata, FKS2 
was successfully amplified for all four isolates of C. nivariensis, 
while FKS1 showed only faint bands. However, subjecting these 
amplicons to PCR sequencing yielded sequences with decent 
qualities. No mutations were observed in the HS1 for FKS2 and 
in FKS1 two of the isolates contained silent mutations. The first 
isolate carried a homozygote and a heterozygote mutations in 
the residues of 628 (A1884T) and 630 (C1888Y), and the second 
isolate harboured a mutation in the residue of 630 (C1888T). All 
these mutations were silent and did not affect the amino acid 
sequence of the HS1 of FKS1.
Genotyping by AFLP
AFLP analysis clustered our isolates with the CBS reference 
and type strains of C. nivariensis and they were grouped in 
two discrete clusters. Three of our isolates (2 N, 5 N and 
100B) from Mashhad and Tehran clustered with CBS 10161, 
while the other isolate from Mashhad (35 N) clustered with 
CBS 9983–9985 (Fig. 2). The isolates 2 N and 5 N that were 
isolated – with an interval of >30 days – from the same patient 
were found to share the same AFLP genotype.
Antifungal susceptibility testing
Based on clinical breakpoints, all of our isolates showed a 
susceptible phenotype for FLC (0.0625–1 µg ml−1), AND and 
MCF (≤0.016 µg ml−1) and AMB (0.5–1 µg ml−1). Based on 
epidemiological cut-off value, our isolates were susceptible 
to ITC (≤0.016–0.0625 µg ml−1), VRC (≤0.016–0.03 µg ml−1), 
PSC (≤0.016–0.125 µg ml−1) and 5-FC (0.0625–0.125 µg ml−1) 
(Table 1).
Fig. 2. AFLP fingerprinting profiles generated for C. nivariensis isolates.
Table 1. MIC of our isolates of C. nivariensis and CBS reference and type strains of C. bracarensis and C. nivariensis determined by EUCAST methodology
Strains MIC values (µg ml−1) 
Fluconazole Itraconazole Voriconazole Posaconazole 5FC AMB Anidulafungin Micafungin
CBS9983 1 0.06 0.6 0.125 0.06 0.5 ≤0.016 ≤0.016
CBS9984 1 0.125 0.6 0.125 0.06 1 ≤0.016 ≤0.016
CBS9985 1 0.06 0.03 0.125 0.06 0.5 ≤0.016 ≤0.016
CBS10161 0.125 ≤0.016 ≤0.016 ≤0.016 0.125 1 ≤0.016 ≤0.016
2N 0.06 ≤0.016 ≤0.016 ≤0.016 0.125 1 ≤0.016 ≤0.016
5N 0.125 ≤0.016 ≤0.016 ≤0.016 0.125 1 ≤0.016 ≤0.016
35 N 0.125 ≤0.016 ≤0.016 ≤0.016 0.125 0.5 ≤0.016 ≤0.016
81–7 1 0.06 0.03 0.125 0.06 1 ≤0.016 ≤0.016
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dISCuSSIon
Despite an increasing number of reported C. nivariensis cases 
from different countries, limited data is presented with regards 
to antifungals' susceptibility pattern, virulence factors, genuine 
distribution and epidemiology, and biological niches of this 
species. Here, we have systematically screened clinical isolates of 
C. glabrata collected from 2015 to 2018 to assess the nation-
wide epidemiology of C. nivariensis in Iran.
C. nivariensis was exclusively found in blood 
samples
Isolates of C. nivariensis were only obtained from blood 
samples, and we did not find this species from other clinical 
samples, such as urine, vaginal swabs, BAL, sputum and stool. 
These four isolates were recovered from three patients (two 
females and one male) and for one of them within 30 days 
two isolates were recovered, which represented two episodes. 
These four cases were reported from two different hospitals. 
The median age of infected patients was 62 years and it seems 
that C. glabrata and C. nivariensis tend to cause infection in 
the elderlies [17]. All of our patients had received broad spec-
trum antibiotics, which is one of the highlighted risk factors 
for development of candidemia [18].
Appropriate identification tool is a prerequisite
As a preliminary screening tool, all of the presumptive isolates 
of C. glabrata were cultured on CHROMagar and isolates of 
C. glabrata and C. nivariensis showed pink and white colora-
tion, respectively, while a 21-plex PCR [12] identified them all 
as C. glabrata species complex. MALDI-TOF MS and nine-plex 
PCR, unequivocally identified four isolates of C. nivariensis in 
agreement with rDNA sequencing. In contrast, Vitek MS does 
not have the ability to identify isolates of C. nivariensis and 
C. bracarensis [19]. Hence, it is recommended that laborato-
ries equipped with this device reidentify isolates of C. glabrata 
with inexpensive alternative means of identification such as 
CHROMagar and/or PCR-based approaches. In our study, 
4.41% (3/68) of candidemia cases caused by members of the 
cryptic complex species of C. glabrata were attributable to 
C. nivariensis. Although, most of studies have shown a low clinical 
prevalence of C. bracarensis and C. nivariensis [10], the preva-
lence we reported here is in agreement with the study conducted 
in Poland, where they did not find C. bracarensis, while they 
showed that C. nivariensis constituted 6% of clinical isolates of 
C. glabrata [20]. The lower clinical prevalence of C. nivariensis 
and C. bracarensis is partially explained by genomic studies, 
where it was shown that these two species are more closely 
related to the non-pathogenic members of the Nakaeseomyces 
clades than to C. glabrata [8]. However, accelerated evolution of 
their genome enable them to become more virulent [8] and with 
an increase in the population of immunocompromised patients 
might lead to a higher prevalence of infections pertained to these 
two species. Moreover, all pathogenic attributes of C. glabrata 
are present even in environmental (non-pathogenic) species of 
Nakaseomyces clade, for example N. delphensis [8]. Furthermore, 
N. delphensis compared to clinical isolates of C. bracarensis was 
found to be pan-azole-resistant (FLC=128, ITC>16, PSC>8, 
VRC>4 µg ml−1) and its MIC values for echinocandins and AMB 
were higher or equal to that of C. bracarensis [21]. As a result, 
expanding appropriate and accurate means of identifications 
will result in a more comprehensive view on the distribution 
and epidemiology, antifungal susceptibility patterns, and even 
pathogenicity of species within the Nakaseomyces clade.
Various genotypes of C. glabrata proved to differ in their 
antifungal susceptibility and mortality rates [22], highlighting 
the importance of using highly resolutive genotyping tech-
niques, such as AFLP, in microbiological investigations. Using 
AFLP, our isolates clustered into two distinct genotypes of 
C. nivariensis, where three of our isolates (one from Tehran 
and two from Mashhad from the same patient) clustered with 
CBS 10161 and the fourth isolate (from Mashhad) clustered 
with CBS 9983, CBS 9984 and CBS 9985.
Variability in antifungal susceptibility patterns and 
clinical outcomes
Our C. nivariensis isolates were susceptible to all tested 
drugs, including AMB, AND, FLC, ITC, MCF, PSC, VRC 
and 5FC (Table  1). On the other hand, some clinical 
isolates of C. nivariensis recovered from blood [23] and 
vaginal swabs [24] showed high MIC values for FLC and 
infected patients were not responsive to this drug. Data 
derived from the literature review revealed that there is a 
strain and geographical variability for antifungal suscep-
tibility patterns of isolates of C. nivariensis and it seems 
that this phenomenon is common for clinical isolates of 
C. glabrata, as well [15, 25]. Although, one of our patients 
that was treated with CSP plus FLC and AMB deoxy-
cholate survived, unfortunately no data was available on 
his follow-up to ensure that he is alive. Moreover, two of 
our patients died despite treatment with FLC plus AMB 
deoxycholate and AMB plus CSP. Considering that there 
is limited information with regards to treatment options 
and outcomes of patients infected with C. nivariensis, it 
appears that the sole reliance on FLZ and CSP does not 
seem enough to resolve candidemia and vaginitis caused 
by this species [24, 26, 27], while a combination of VRC 
plus MCF followed by micafungin alone [23] or CSP plus 
catheter removal [27] for candidemia cases and oral VCZ 
[24] for recurrent vaginitis cases showed successful treat-
ment outcomes. A higher efficacy of MCF for clearance of 
infections caused by C. glabrata might be behind the fact 
that this drug causes mutations in HS1 of FKS1 and FKS2 
approximately 11 times less than CSP and five times AND 
[28]. Possible misidentification cases of C. nivariensis and 
C. bracarensis as C. glabrata and high MIC values for azole 
drugs might prompt clinicians to use echinocandins for 
treatment of candidemia cases caused by C. nivariensis. On 
the other hand, mutations in HS1 of FKS1 and FKS2 are a 
predictor of therapeutic failure of echinocandins against 
C. glabrata [29], hence, screening of mutations in HS1 of 
FKS1 and FKS2 could be an imperative initiative to detect 
resistance isolates of C. nivariensis and C. bracarensis to 
echninocandins. Lack of amino acid substitution in the HS1 
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of FKS1 and FKS2 was in agreement with low MIC values 
obtained for aniulafungin and micafungin.
Where is the original biological niche of  
C. nivariensis?
Comparative genomic studies have disclosed that C. glabrata 
is well-adapted to the human gut as its main biological niche, 
while C. nivariensis might have adapted to other environmental 
niches [8]. This is in line with the findings of environmental 
sampling studies from Thailand that isolated C. nivariensis 
from leaves of sugarcane [30], barks and soil [10], while 
C. glabrata was not cultured. So far, all C. bracarensis isolates 
are from clinical sources, and the majority of C. nivariensis 
isolates has a clinical source. This might raise the question if 
these two species are part of human mycobiota and they will 
invade the bloodstream, once there is an opportunity. This 
might be further reinforced by the fact that one of the patients 
that had a duodenal perforation [26] developed C. nivariensis 
candidemia. Hence, it could be speculated that this species 
occur in the environment as the main biological niche and 
subsequently it undergoes adaptation to the human host. In 
order to address this question, development and application 
of sensitive and accurate metagenomics platforms might be 
a useful solution. Once established, subjecting human and 
environmental-derived samples might elucidate the real 
biological niches of these species.
Conclusion
In summary, we report four clinical isolates of C. nivariensis 
among a set that was presumptively identified as C. glabrata 
and that were all recovered from blood samples. Taking 
advantage of accurate means of identification, such as 
molecular assays and MALDI-TOF MS will aid in unravelling 
the epidemiology of these cryptic yeast species. Utilization of 
these techniques will even have a significant impact on our 
general knowledge of these species. For instance, although it 
was thought that C. nivariensis was isolated in 2005 in Spain 
for the first time [6], with the aid of accurate means of iden-
tification, the first documented isolates of this species dated 
back to 1996 in Argentina [31]. Once isolated, we will have 
the possibility to take a global initiative to study the lacking 
pieces of the puzzles of genotyping, antifungal susceptibility 
patterns, and virulence of members of this cryptic complex 
species.
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